Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nigmeta
- Development stage
- Unknown
- Lead developer
- SNIG Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nigmeta is a branded generic formulation of metoprolol succinate, developed and marketed by SNIG Pharmaceuticals Pvt Ltd. It is a cardioselective beta-1 adrenergic receptor blocker used for the management of various cardiovascular conditions, including hypertension, angina pectoris, and cardiac arrhythmias. Additionally, it is indicated for the prevention of migraines and for reducing the risk of future heart attacks and strokes. As an extended-release tablet, it provides a sustained therapeutic effect by inhibiting the response to adrenergic stimuli, thereby decreasing heart rate, cardiac output, and blood pressure.
- Brand names
- Nigmeta
- Other names
- metoprolol succinate
02
Targets
ADRB1 (β1)
Beyond the preview
Go deeper on Nigmeta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nigmeta.